8-K: Immix Biopharma Changes Accounting Firms, Appoints Crowe LLP

Immix Biopharma has changed its independent registered public accounting firm from KMJ Corbin & Company LLP to Crowe LLP, effective July 17, 2024.

Summary

• Immix Biopharma has replaced its independent registered public accounting firm, KMJ Corbin & Company LLP, with Crowe LLP.
• The change was effective on July 17, 2024, and was approved by the company's Audit Committee.
• KMJ's reports on the company's financial statements for the fiscal years ending December 31, 2023 and 2022 did not contain any adverse opinions or modifications.
• There were no disagreements between Immix Biopharma and KMJ on accounting principles, financial statement disclosures, or auditing procedures during the past two fiscal years and subsequent interim period.
• Immix Biopharma did not consult with Crowe regarding accounting principles or audit opinions prior to their appointment.

Sentiment

Score: 7

Explanation: The document indicates a routine change in accounting firms with no apparent issues, suggesting a neutral to slightly positive sentiment.

Positives

• The transition of accounting firms was smooth, with no reported disagreements or issues.
• KMJ's audit reports for the past two fiscal years were clean, indicating sound financial reporting practices.
• The company's Audit Committee approved the change, suggesting proper governance.

Risks

• The change in accounting firms could potentially introduce some short-term disruption, although no issues were reported.
• Any future disagreements with the new accounting firm could lead to complications.

Management Comments

• The company, through and with the approval of its Audit Committee, dismissed KMJ as the company's independent registered accounting firm, and appointed Crowe as its independent registered public accounting firm.

Industry Context

Changes in accounting firms are not uncommon, but it is important for companies to ensure a smooth transition to maintain investor confidence and financial reporting integrity. The move of KMJ staff to Crowe is a unique situation that has resulted in this change.

Comparison to Industry Standards

• The transition of accounting firms is a standard practice in the industry, and Immix Biopharma's process appears to be in line with typical procedures.
• Many companies change auditors periodically to ensure independence and fresh perspectives.
• The lack of disagreements with the previous auditor is a positive sign, as it indicates a healthy relationship and no underlying issues.

Stakeholder Impact

• The change in accounting firms is unlikely to have a significant impact on stakeholders, as it appears to be a routine administrative change.
• Shareholders may view the smooth transition as a positive sign of good corporate governance.

Key Dates

Keywords

accounting firm, audit, Crowe LLP, KMJ Corbin & Company LLP, financial statements, Immix Biopharma